Recent studies have suggested that elevated expression of MAPT predicts better survival outcomes in pediatric neuroblastoma, breast cancer, renal clear cell cancer, and low-grade glioma, which is consistent with the results of the present study [31–34]. This evidence concerns the gene MAPT and breast carcinoma.